News and analysis on the global poultry
and animal feed industries.
Pig Nutrition / Animal Feed Safety
on October 27, 2014

Biomin’s FUMzyme authorized by EU

Can be used as substance for reduction of mycotoxin contamination of feed

FUMzyme, part of the Mycofix product line of Biomin, is the first-ever purified enzyme authorized by the EU proven to biotransform fumonisins into nontoxic metabolites.

FUMzyme was originally isolated from the fumonisin degrading soil bacteria Sphingopyxis sp. MTA 144 and identified as fumonisin esterase by the Biomin Research Center.

The product is effective in degrading fumonisins to compounds of significantly lower toxicity in the gastrointestinal tract of animals. The sphinganine/sphingosine ratio, considered the most sensitive endpoint for fumonisin toxicosis, was included as an important parameter in several short- and long-term feeding studies conducted with pigs.

These trials consistently demonstrated that the addition of FUMzyme significantly reduced the sphinganine/sphingosine ratio of pigs fed fumonisin-contaminated diets. Sphinganine/sphingosine values generally returned to levels seen in animals fed corresponding diets free from fumonisins.

Until now, the binding of fumonisins to adsorptive substances was the only solution available to counter fumonisin intoxication. Due to the molecular structure of these mycotoxins and pH dependence of the reaction, fumonisins are only insufficiently adsorbed by mycotoxin-binding products in the gastrointestinal tract.

According to current Biomin Mycotoxin Survey results of 2014 in which more than 3,500 samples worldwide were analyzed, fumonisins were found in 82 percent of all corn samples with an average contamination of over 2,200 ppb.

In 2013, Biomin became the first company to receive the European Commission authorization for feed additives with mycotoxin-counteracting properties. The authorizations were for the deoxynivalenol-biotransforming product Biomin BBSH 797 and the aflatoxin-binding bentonite Mycofix Secure.

Comments powered by Disqus